Published in J Bone Miner Res on July 01, 2009
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. Cell Metab (2015) 1.56
Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology (2012) 1.32
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem (2010) 1.10
Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling. J Biol Chem (2013) 0.98
RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J Bone Miner Res (2014) 0.94
Emerging therapies for the treatment of osteoporosis. J Midlife Health (2013) 0.93
Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporos Int (2011) 0.83
Secondary osteoporosis in collagen-induced arthritis rats. J Bone Miner Metab (2015) 0.78
Canonical Notch activation in osteocytes causes osteopetrosis. Am J Physiol Endocrinol Metab (2015) 0.77
Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture. Int J Endocrinol (2013) 0.77
In Vivo siRNA Delivery Using JC Virus-like Particles Decreases the Expression of RANKL in Rats. Mol Ther Nucleic Acids (2016) 0.75
The Dmp1-SOST Transgene Interacts With and Downregulates the Dmp1-Cre Transgene and the Rosa(Notch) Allele. J Cell Biochem (2015) 0.75
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest (2006) 3.72
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Different functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl Acad Sci U S A (2004) 2.85
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol (2002) 2.35
A transforming metal nanocomposite with large elastic strain, low modulus, and high strength. Science (2013) 2.28
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Nebulin-deficient mice exhibit shorter thin filament lengths and reduced contractile function in skeletal muscle. J Cell Biol (2006) 2.00
Rapid skeletal turnover in a radiographic mimic of osteopetrosis. J Bone Miner Res (2014) 2.00
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development (2005) 1.92
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol (2005) 1.85
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood (2002) 1.84
Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev (2012) 1.82
Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother (2010) 1.82
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology (2005) 1.78
Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J (2004) 1.73
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70
Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res (2009) 1.68
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis (2010) 1.67
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res (2010) 1.65
Molecular mechanism for the umami taste synergism. Proc Natl Acad Sci U S A (2008) 1.53
Superhigh-throughput needleless electrospinning using a rotary cone as spinneret. Small (2010) 1.52
Endothelial expression of bone morphogenetic protein receptor type 1a is required for atrioventricular valve formation. Ann Thorac Surg (2008) 1.51
Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol (1985) (2008) 1.49
Knowledge and personal use of menopausal hormone therapy among Chinese obstetrician-gynecologists: results of a survey. Menopause (2014) 1.44
Bitter taste receptors influence glucose homeostasis. PLoS One (2008) 1.44
The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev (2012) 1.43
Parallel preoptic pathways for thermoregulation. J Neurosci (2009) 1.43
Impact of 120-W 2-μm continuous wave laser vapoenucleation of the prostate on sexual function. Lasers Med Sci (2013) 1.42
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
Specific alleles of bitter receptor genes influence human sensitivity to the bitterness of aloin and saccharin. Curr Biol (2007) 1.37
Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone (2010) 1.36
Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep (2013) 1.35
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res (2003) 1.33
Molecular mechanism of the sweet taste enhancers. Proc Natl Acad Sci U S A (2010) 1.32
Nanomechanical characterization of one-step combustion-synthesized Al(4)B(2)O(9) and Al(18)B(4)O(33) nanowires. Nano Lett (2007) 1.31
The effects of Gd3+ substitution on the crystal structure, site symmetry, and photoluminescence of Y/Eu layered rare-earth hydroxide (LRH) nanoplates. Dalton Trans (2011) 1.31
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
Freestanding three-dimensional graphene/MnO2 composite networks as ultralight and flexible supercapacitor electrodes. ACS Nano (2012) 1.30
Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res (2013) 1.29
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One (2010) 1.29
Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum (2009) 1.27
PINCH1 plays an essential role in early murine embryonic development but is dispensable in ventricular cardiomyocytes. Mol Cell Biol (2005) 1.27
Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol (2009) 1.23
Embryonic survival and severity of cardiac and craniofacial defects are affected by genetic background in fibroblast growth factor-16 null mice. DNA Cell Biol (2010) 1.22
Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum Mol Genet (2008) 1.22
Electrical self-healing of mechanically damaged zinc oxide nanobelts. Nano Lett (2010) 1.21
P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. J Biol Chem (2006) 1.21
Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res (2010) 1.18
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol (2010) 1.16
Nuclear Ca2+ sparks and waves mediated by inositol 1,4,5-trisphosphate receptors in neonatal rat cardiomyocytes. Cell Calcium (2007) 1.14
Flexible Zn2SnO4/MnO2 core/shell nanocable-carbon microfiber hybrid composites for high-performance supercapacitor electrodes. Nano Lett (2011) 1.14